Streetbeat News

Price Targets

AMRN

Jefferies has downgraded Amarin's stock from Buy to Hold and reduced its price target from $3 to $1, causing the shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 6:10 pm

FTCH

Farfetch's stock has been downgraded from Buy to Sell by Societe Generale, with a new price target of $1.5. This has led to a decrease in Farfetch's share price.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 6:08 pm

SRRK

Jefferies has upgraded Scholar Rock's stock from Hold to Buy and set a price target of $20. This has resulted in Scholar Rock's shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 6:03 pm

NBN

Piper Sandler analyst Alexander Twerdahl has maintained an Overweight rating on Northeast Bank (NASDAQ:NBN) and raised the price target from $52 to $54.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 5:55 pm

RARE

Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) but lowered the price target from $135 to $130.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 5:53 pm

GOOGL

Piper Sandler analyst Thomas Champion has maintained an Overweight rating on Alphabet (NASDAQ:GOOGL) and raised the price target from $147 to $150.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 5:49 pm

TXN

Truist Securities analyst William Stein has maintained a 'Hold' rating on Texas Instruments (NASDAQ:TXN) but lowered the price target from $165 to $150.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 5:46 pm

SPOT

Truist Securities analyst Matthew Thornton has maintained a 'Buy' rating on Spotify Technology (NYSE:SPOT) and raised the price target from $176 to $190.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 5:44 pm

PII

Truist Securities analyst Michael Swartz has maintained a 'Hold' rating on Polaris (NYSE:PII) and lowered the price target from $125 to $100.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 5:42 pm

HCA

Truist Securities analyst David Macdonald has maintained a 'Buy' rating on HCA Healthcare (NYSE:HCA), but lowered the price target from $340 to $300.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 5:40 pm